How do injectable testosterone therapies affect lipid levels and the risk of hyperlipidemia?

Testosterone Injections and Hyperlipidemia

Physiologic doses of injectable testosterone therapy have a neutral to potentially beneficial effect on lipid profiles and do not cause clinically significant hyperlipidemia. 1, 2

Key Lipid Effects at Physiologic Replacement Doses

Based on the most authoritative guideline evidence from the New England Journal of Medicine and the Endocrine Society, here's what happens with testosterone injections at appropriate replacement doses:

HDL Cholesterol (The "Good" Cholesterol)

• Minimal to no change with physiologic dosing 1
• A meta-analysis of intramuscular testosterone esters showed HDL was reduced in only 3 studies but unchanged in 15 studies 1, 3
• Any HDL reduction is dose-dependent: only supraphysiologic doses (600 mg/week, far above typical replacement) caused significant HDL decreases 1
• At standard replacement doses (25-300 mg/week), HDL either remained stable or showed small, non-significant increases 1

LDL Cholesterol (The "Bad" Cholesterol)

• Unchanged or reduced in 14 of 15 studies examining intramuscular testosterone 1
• Reductions of 5-21 mg/dL observed in hypogonadal men 4, 3
• This represents a favorable cardiovascular effect

Total Cholesterol

• Reduced in 5 studies, increased in 2, unchanged in 12 1
• When changes occur, they typically show decreases of 14-27 mg/dL 4, 3
• Overall trend is neutral to beneficial

Triglycerides

• No significant changes at any physiologic testosterone dose 1
• Remained stable across multiple controlled studies

The Critical Dose-Dependent Relationship

The relationship between testosterone and lipids is highly dose-dependent, which explains much of the confusion in the literature:

• Physiologic replacement doses (100-200 mg every 2 weeks): Neutral to beneficial lipid effects 1
• Supraphysiologic/abuse doses (≥600 mg/week): Significant HDL suppression and adverse lipid changes 1, 5
• Oral non-aromatizable androgens: Most problematic for HDL reduction 1

Clinical Guideline Recommendations

The 2020 Endocrine Society explicitly states: testosterone therapy should NOT be used as an approach to improve dyslipidemia or cardiovascular disease risk 2. This means:

• Don't prescribe testosterone to treat high cholesterol
• Don't expect testosterone to worsen existing hyperlipidemia at replacement doses
• Monitor lipids before and during therapy, but expect neutral effects

Important Caveats and Pitfalls

Route of Administration Matters

Injectable testosterone (intramuscular) and transdermal preparations show similar neutral effects on lipids when dosed appropriately 1. A 24-week multicenter study found no significant differences in HDL or total cholesterol/HDL ratio between intramuscular and transdermal routes 1.

What About Cardiovascular Risk?

The evidence suggests testosterone replacement at physiologic doses does not increase cardiovascular risk through lipid mechanisms 1:

• Men with higher endogenous testosterone had lower rates of severe aortic atherosclerosis (relative risk 0.2-0.4) 1
• No increased incidence of myocardial infarction, stroke, or angina in testosterone replacement studies 1

The Real Risk: Polycythemia, Not Hyperlipidemia

The primary cardiovascular concern with testosterone injections is erythrocytosis (elevated hematocrit), not lipid changes 1:

• 43.8% of patients on intramuscular injections developed elevated hematocrit (>52%) 1
• This poses greater cardiovascular risk than any lipid changes, especially in elderly patients with existing vascular disease

Practical Clinical Approach

When prescribing testosterone injections:

1. Obtain baseline lipid panel before starting therapy 2

2. Use physiologic replacement doses only (typically 100-200 mg testosterone enanthate or cypionate every 2 weeks)

3. Recheck lipids at 3-6 months, but expect minimal changes 1

4. Focus monitoring on hematocrit (every 3-6 months), which is the more significant cardiovascular risk 1

5. If HDL drops significantly, verify the patient isn't using supraphysiologic doses or oral androgens 1, 5

6. Investigate anabolic steroid abuse if HDL falls below 30 mg/dL, especially without hypertriglyceridemia 2

Bottom Line for Clinical Practice

You can reassure patients that properly dosed testosterone injections will not cause hyperlipidemia and may actually improve their lipid profile modestly through reductions in total and LDL cholesterol. 1, 4 The evidence consistently shows a neutral effect on cardiovascular lipid risk when testosterone is used at physiologic replacement doses for legitimate hypogonadism.